Prevalence and Risk Factors for Cardiac and Liver Iron Overload in Adults with Thalassemia in Malaysia

References

• Borgna Pignatti C, Cappellini M, Stefano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054(1):40–47.
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(?):42–49.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14(3):183–190.
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–1936.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2. Hemoglobin. 2006;30(2):219–227.
   PubMed Web of Science ®Google Scholar
• Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica. 2013;98(9):1368–1374.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48–54.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842–848.
   PubMed Web of Science ®Google Scholar
• Westwood M, Anderson LJ, Firmin DN, et al. A single breath hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33–39.
   PubMed Web of Science ®Google Scholar
• Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853–4855.
   PubMed Web of Science ®Google Scholar
• Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32(2):315–319.
   PubMed Web of Science ®Google Scholar
• Wahidiyat PA, Liauw F, Sekarsari D, et al. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017;22(8):501–507.
   PubMed Web of Science ®Google Scholar
• Krittayaphong R, Viprakasit V, Saiviroonporn P, et al. Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: a multicenter study based on real-world data. Blood Cells Mol Dis. 2017;66:24–30.
   PubMed Web of Science ®Google Scholar
• Capellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT), 3rd ed. Nicosia (Cyprus): Thalassaemia Internati onal Federation; 2014.
   Google Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051–2052.
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–1968.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica. 2007;92(1):131–132.
   PubMed Web of Science ®Google Scholar
• Tanner M, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8(3):543–547.
   PubMed Web of Science ®Google Scholar
• Jensen PD, Jensen FT, Christensen T, et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632–4639.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang H, Yang Q, et al. Value of severe liver iron overload for assessing heart iron levels in thalassemia major patients. J Magn Reson Imaging. 2016;44(4):880–889.
   PubMed Web of Science ®Google Scholar
• Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973–2978.
   PubMed Web of Science ®Google Scholar
• Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol. 2009;82(5):381–387.
   PubMed Web of Science ®Google Scholar
• Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94(12):1777–1778.
   PubMed Web of Science ®Google Scholar
• Marsella M, Borgna-Pignatti C, Meloni A, et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. Haematologica. 2011;96(4):515–520.
   PubMed Web of Science ®Google Scholar
• Roghi A, Cappellini, MD, Wood JC, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010;89:585–589.
   PubMed Web of Science ®Google Scholar
• Puliyel M, Sposto R, Berdoukas VA, et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol. 2014;89(4):391–394.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–S19.
   PubMed Web of Science ®Google Scholar
• Christoforidis A, Haritandi A, Tsitouridis I, et al. Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients. J Pediatr Hematol Oncol. 2006;28(5):311–315.
   PubMed Web of Science ®Google Scholar